Galderma, a leading specialist in dermatology, has shared new clinical findings demonstrating that nemolizumab can quickly reduce itch and improve sleep in patients with atopic dermatitis and prurigo nodularis. Data from post-hoc analyses of the phase III ARCADIA and OLYMPIA trials, published in the Journal of the European Academy of Dermatology and Venereology, show that some patients experienced measurable relief within 48 hours of starting treatment.
Health Technology Insights: ZS Acquires Torrent Consulting to Fuel Salesforce’s Healthcare, Life Sciences AI Solutions
Nemolizumab is the first approved monoclonal antibody to specifically target the IL-31 receptor alpha, blocking the signaling of IL-31, a neuroimmune cytokine responsible for driving itch and related symptoms in both atopic dermatitis and prurigo nodularis. These findings emphasize the importance of targeting the IL-31 pathway to achieve rapid symptom improvement.
Atopic dermatitis and prurigo nodularis are chronic skin conditions that severely impact patients’ quality of life. Persistent itch, skin lesions, and disrupted sleep are among the most challenging symptoms, with studies showing that 87% of patients with atopic dermatitis and 88% of patients with prurigo nodularis identify itch as their worst symptom. Rapid relief from itch and sleep disturbances is therefore critical to improving patient well-being.
Health Technology Insights: HealthLynked Names Duncan McGillivray COO to Drive Growth
The analyses included data from ARCADIA 1 and 2 trials for atopic dermatitis and OLYMPIA 1 and 2 trials for prurigo nodularis, in which patients recorded daily assessments of itch intensity and sleep disturbance. Results showed that within two days, nemolizumab significantly reduced itch compared to placebo, with 10.7% of atopic dermatitis patients and 17.2% of prurigo nodularis patients experiencing early improvement. Sleep quality also improved within 48 hours, affecting 9.9% of patients with atopic dermatitis and 13.4% of patients with prurigo nodularis compared to placebo. By Day 14, a quarter of atopic dermatitis patients and more than a third of prurigo nodularis patients achieved meaningful responses in both itch and sleep outcomes. Individual trial analyses consistently demonstrated significant improvement in Peak Pruritus Numerical Rating Scale scores as early as Day 2.
These findings reinforce nemolizumab’s ability to provide fast and clinically meaningful relief for patients suffering from the most burdensome aspects of atopic dermatitis and prurigo nodularis. By addressing both itch and sleep disturbances rapidly, the treatment has the potential to significantly improve daily life for those living with these chronic conditions.
The Chief Medical Officer at Galderma, stated that these results highlight the impact of IL-31 pathway inhibition in achieving rapid symptom relief. The company remains committed to developing innovative solutions that address the unmet needs of patients with dermatologic conditions and improve overall quality of life.
Health Technology Insights: Omnicell Titan XT: Next-Gen Automated Medication System
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
